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Summary
Epithelial-mesenchymal crosstalk is essential for tissue morphogenesis, but incompletely
understood. Postnatal mammary gland development requires epidermal growth factor receptor
(EGFR) and its ligand amphiregulin (AREG), which generally must be cleaved from its
transmembrane form in order to function. As the transmembrane metalloproteinase ADAM17 can
process AREG in culture and Adam17−/− mice tend to phenocopy Egfr−/− mice, we examined the
role of each of these molecules in mammary development. Tissue recombination and transplantation
studies revealed that EGFR phosphorylation and ductal development occur only when ADAM17 and
AREG are expressed on mammary epithelial cells, whereas EGFR is required stromally, and that
local AREG administration can rescue Adam17−/− transplants. Several EGFR agonists also
stimulated Adam17−/− mammary organoid growth in culture, but only AREG was expressed
abundantly in the developing ductal system in vivo. Thus, ADAM17 plays a crucial role in mammary
morphogenesis by releasing AREG from mammary epithelial cells, thereby eliciting paracrine
activation of stromal EGFR and reciprocal responses that regulate mammary epithelial development.
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Introduction
Branching morphogenesis is a fundamental process of organogenesis. The mammary gland,
unlike other branched tissues, undergoes most of its morphogenesis during adolescent
development (Wiseman and Werb, 2002). In mice, the rudimentary ductal tree that forms
during late embryogenesis undergoes just enough growth to keep pace with normal body
growth until puberty, at which point robust branching morphogenesis begins. Bulbous terminal
end buds (TEBs) form at the tips of the ducts and penetrate the mammary fat pad, new primary
ducts form by bifurcation of the TEBs, and secondary side-branches sprout laterally from the
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trailing ducts until the entire fat pad is filled by an extensive system of branched ducts by 8–
10 weeks of age. The mature ductal tree, in turn, forms the foundation for future phases of
mammary development and function. Thus, alveolar structures develop along the entire ductal
tree during pregnancy, produce milk throughout lactation, and regress during post-weaning
mammary involution, leaving the ductal tree intact and ready for further rounds of
lobuloalveolar expansion and differentiation.
Epidermal growth factor receptor (EGFR/ERBB1) is a transmembrane tyrosine kinase that is
activated upon binding EGF, transforming growth factor α (TGFα), amphiregulin (AREG),
heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC), epiregulin (EPIR) or
epigen (EPGN), each of which is expressed as a transmembrane precursor that is proteolytically
shed from the cell surface (Harris et al., 2003). Once occupied, EGFR dimerizes with another
EGFR monomer or one of three related receptors, ERBB2, ERBB3 or ERBB4. Notably,
mammary development is impaired in waved 2 mutant mice that harbor a kinase-impaired
EGFR (Fowler et al., 1995; Sebastian et al., 1998) and in transgenic mice that express a
mammary-targeted, dominant-negative EGFR (Xie et al., 1997). Egfr mRNA and protein are
abundant in mammary stroma (Luetteke et al., 1999; Schroeder and Lee, 1998). Indeed, EGF
induces EGFR phosphorylation in gland-free fat pads (Sebastian et al., 1998) and significantly
more 125I-EGF binds to stromal cells surrounding TEBs than to any other area of the developing
gland (Coleman et al., 1988). Notably, Egfr−/− glands show impaired ductal outgrowth when
grown under the renal capsules of host mice, and when wild-type or Egfr−/− ducts are surgically
recombined with fat pads of the same or opposite genotype, the ducts grow regardless of
genotype if the stroma contains EGFR, but not if it lacks EGFR. This indicates that stromal
rather than epithelial EGFR is essential for ductal development (Wiesen et al., 1999).
Nevertheless, Egfr−/− transplants do undergo alveolar differentiation in response to prolactin
from nearby pituitary isografts, suggesting that EGFR is essential for ductal, but not alveolar,
development.
The importance of EGFR also means that one or more of its ligands must influence mammary
development. At least six EGFR agonists are expressed during mammary development, but
only AREG is strongly upregulated at puberty and dramatically downregulated during and after
pregnancy (D’Cruz et al., 2002; Schroeder and Lee, 1998), a pattern consistent with the
importance of EGFR in post-pubertal mammary development. Indeed, ductal outgrowth is
severely impaired in triple-null mice lacking AREG, EGF and TGFα, which are lactation
incompetent, and variably impaired in mice lacking only AREG (Luetteke et al., 1999). As
neither ductal outgrowth nor lactation is affected by elimination of EGF, TGFα, HB-EGF or
BTC alone or in various combinations (Jackson et al., 2003; Luetteke et al., 1999), AREG must
be uniquely required for this process.
Like all EGFR ligands, AREG is expressed as a transmembrane precursor that is generally
cleaved and released to activate its receptor. Extensive data indicate that various members of
the ADAM (a disintegrin and metalloproteinase) family of cell surface enzymes, including
ADAM17 (TNFα-converting enzyme or TACE), are responsible for the release of EGFR
ligands, including AREG, in vitro (Hinkle et al., 2004; Sahin et al., 2004; Sunnarborg et al.,
2002) and even cell contact-dependent juxtacrine activation of EGFR may require ADAM17-
mediated processing of EGFR agonists (Borrell-Pages et al., 2003). However, no genetic
evidence supporting a role for ADAM17 as a physiological AREG sheddase has yet been
provided. By contrast, Adam17−/− mice (Peschon et al., 1998a; Shi et al., 2003) display the
altered eyelid, hair and whisker development of TGFα-deficient mice (Luetteke et al., 1993;
Mann et al., 1993), the aberrant heart valve development of HB-EGF-null and uncleavable
HB-EGF knock-in mice (Iwamoto et al., 2003; Jackson et al., 2003; Yamazaki et al., 2003),
and the broad epithelial defects and perinatal lethality of Egfr−/− mice (Miettinen et al., 1995;
Sibilia and Wagner, 1995; Threadgill et al., 1995). Moreover, studies using single-, triple- and
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quadruple-gene knockout mice lacking ADAM9, ADAM12, ADAM15 and/or ADAM17 show
that only ADAM17 is responsible for the eyelid and heart phenotypes and is thus required for
efficient processing of TGFα and HB-EGF in these tissues (Sahin et al., 2004).
Although the above data suggest that ADAM17 processes EGFR ligands in certain embryonic
situations, its role in mediating paracrine crosstalk between differing cell-types postnatally
remains unexplored. In this study, we use tissue recombination methods to show that EGFR
is indeed required in the stroma of the developing mammary gland, whereas the requirement
for AREG to form a competent ductal tree rather than an inadequate bush resides in the
epithelium, and that ADAM17, which can process AREG, is also required in the epithelium
in a paracrine pathway that is essential for normal branching morphogenesis.
Materials and methods
Mammary transplantation
Adam17−/− and Areg−/− mice were generated on a mixed 129/C57Bl-6 genetic background and
Egfr−/− mice were generated from heterozygous breeding pairs on an out-bred 129SV/J×Swiss
Black-CD1 background. Unless otherwise indicated, timed pregnant females were sacrificed
18 days after the appearance of a vaginal plug (gestational day E18.5) and the uteri and embryos
removed under sterile conditions. Genotypes were determined from tail DNA using published
PCR protocols (Luetteke et al., 1999; Shi et al., 2003; Wiesen et al., 1999) and by the presence
of open eyelids in Adam17−/− and Egfr−/− embryos. Intact female nude mice were from Charles
River.
Recombined mammary transplants were prepared as previously described (Wiesen et al.,
1999). The rudimentary ductal tree was microdissected from the abdominal 4 fat pad, trimmed
of excess stroma and placed onto a gland-free embryonic or neonatal fat pad. The recombined
epithelium and stroma were allowed to adhere to one another by overnight culture on solidified
agar plates containing 0.5% Bacto agar (Difco), 10% fetal bovine serum, 100 U/ml penicillin
G and 100 μg/ml streptomycin in DME-H16 medium enriched with 6 mM L-glutamine.
Recombined and non-recombined glands were placed under the renal capsules of nude mice
with intact ovaries and allowed to grow for 2–6 weeks with or without subcutaneous 1.7 mg
60-day slow-release 17β-estradiol pellets or adjacent 10 μg 21-day AREG micropellets
(Innovative Research of America). Embryonic mammary glands were also transplanted to
surgically cleared host fat pads as described elsewhere (Wiesen et al., 1999). Morphometry
was performed on digital images of carmine-stained mammary whole mounts using FoveaPro3.
All experiments were performed in accordance with protocols approved by the UCSF and UNC
Committees on Animal Research.
Mammary organoid culture
Embryonic and neonatal mammary organoids were prepared in a similar manner to that
described for adult organoids (Simian et al., 2001). Rudimentary ductal trees were
microdissected from the surrounding stroma, pooled and swirled at 100 rpm for 30 minutes at
37°C in DMEM/F12 medium containing 0.2% collagenase A (Sigma), 0.2% trypsin (Life
Technologies), 5% fetal bovine serum, 5 μg/ml insulin and 50 μg/ml gentamicin. The resulting
suspension was spun at 300 g for 5 minutes and the pellets gently agitated at room temperature
for 2 minutes in DMEM/F12 with 40 U/ml DNase I (Sigma). Cell clusters and dissociated
single cells were pelleted at 300 g, washed with DMEM/F12, re-centrifuged and gently
resuspended in ice-cold growth factor-reduced Matrigel (Becton Dickinson). The suspended
organoids were transferred to 48-well plates over a thin cell-free layer of Matrigel and allowed
to gel at 37°C. Following gel formation, 300 μl of basal medium (5 mg/ml insulin, 5 mg/ml
transferrin, 5 μg/ml selenium, 100 U/ml penicillin G and 100 μg/ml streptomycin in DMEM/
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F12) was added with or without growth factors, and the organoids cultured in a humidified 5%
CO2 incubator at 37°C. Growth was observed over 7 days in the presence or absence of 5 nM
murine TNFα or human AREG, HB-EGF or NRG1β1 (R&D Systems), or 5 nM rat TGFα or
human EGF, FGF1, FGF2, FGF7 or FGF10 (Sigma).
Expression profiling
TEB, duct and distal stroma regions of mammary glands 2–5 were independently
microdissected from anesthetized 5-week-old β-actin-GFP reporter mice (Jackson Laboratory)
using a Leica MZFLIII fluorescence microscope. RNA was extracted with Trizol Reagent (Tel-
Test), reverse transcribed in the presence of amino-allyl-dUTP, coupled to CyScribe dyes
(Amersham), and the unamplified Cy5-labeled TEB or duct cDNAs and Cy3-labeled stromal
cDNAs were hybridized to 70-mer oligonucleotide microarrays with 19,500 features (Operon,
mouse version 2.0), as described elsewhere (Barczak et al., 2003). Differential expression
values in the text were obtained by converting the lowest normalized, log2-transformed gene
expression ratios M=log2(Cy5/Cy3) and average overall signal intensities A=0.5[log2(Cy5)
+log2(Cy3)] to linear values for each of six TEB versus distal stroma and six duct versus distal
stroma arrays.
Protein analysis
Tissues were extracted on ice in four volumes (w/v) of 20 mM HEPES, pH 7.4, 150 mM NaCl,
1% Triton X-100 buffer containing protease and phosphatase inhibitors (2 mM EDTA, 2 mM
EGTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM PMSF, 1 mM sodium orthovanadate,
20 mM sodium fluoride, 50 μM sodium molybdate, 2.5 mM sodium pyrophosphate and 1 mM
β-glycerophosphate) by Polytron homogenization and centrifugation. Supernatant proteins
were resolved by SDS-PAGE and transferred to PVDF membranes for western blots or
immunoprecipitated with rabbit anti-mouse EGFR (Upstate, 1 μg/125 μg of protein) and
protein A agarose in Tris-buffered saline containing 0.5% NP-40 and protease and phosphatase
inhibitors. Immunoblotting was performed using mouse anti-phosphotyrosine (4G10, Upstate,
1:1000), rabbit anti-phosphoEGFR (Y1068, Cell Signaling, 1:1000), rabbit anti-mouse EGFR
(Upstate, 1:1000), rabbit anti-mouse keratin 14 (Covance, 1:20,000), goat anti-actin (Santa
Cruz, 1:2000), and HRP-conjugated donkey anti-rabbit, mouse and goat IgG secondary
antibodies (Amersham, 1:2000) followed by enhanced chemiluminescence autoradiography.
Statistical analysis
Mean values are provided with standard deviations and were compared by unpaired, two-tailed
t-tests. Array-based statistics were adjusted for multiple comparisons using the Benjamini-
Hochberg method of controlling for the false discovery rate (Benjamini and Hochberg,
1995).
Results
Epithelial AREG is required for mammary development
Our prior data show that AREG is required for normal mammary morphogenesis (Luetteke et
al., 1999). However, several EGFR ligands can rescue ductal development in ovariectomized
and estrogen receptor α (ERα)-deficient mice (Coleman et al., 1988; Kenney et al., 2003;
Kenney et al., 1996; Snedeker et al., 1991); so why are they unable to compensate for the
absence of AREG in vivo? To address this, we harvested TEBs together with their immediate
surrounding stroma and ducts with their own surrounding stroma from 5-week-old mice and
compared their respective gene expression profiles with those of distal, epithelium-free stroma
using high-density oligonucleotide arrays. Twelve arrays run on pooled samples from two mice
each revealed strong AREG expression that was 13.0±3.9-fold higher in and around TEBs and
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10.2±4.3-fold higher in and around ducts than in distal, epithelium-free stroma (Hochberg’s
P<0.0001 and 0.005, respectively) (Fig. 1). AREG was also the only EGFR ligand with a mean
overall signal intensity from the TEB plus distal stroma (or duct plus distal stroma)
compartments that was well above the threshold needed to distinguish true signal from noise,
suggesting that other EGFR ligands may be absent or weakly expressed during ductal
development (see Tables S1 and S2, and Fig. S1 in supplementary material). The only other
ERBB ligand on the array that was highly expressed was the ERBB3/ERBB4 ligand neuregulin
4 (NRG4), which was more highly expressed in the stroma than in TEBs or ducts (P<0.0005),
though its own possible role in ductal development remains unclear. Because our method
reveals relative expression in the epithelial plus adjacent stromal compartments versus distal,
epithelium-free stroma, we cannot rule out the possibility that AREG is weakly expressed in
the stroma or induced in the immediate periepithelial stroma. Nevertheless, our results are
consistent with in situ hybridization data that show substantial and exclusive expression of
AREG in the epithelium of developing ducts and TEBs (D’Cruz et al., 2002; Luetteke et al.,
1999), further suggesting that although other EGFR ligands can support ductal growth in
culture and in mice, only AREG is expressed at significant levels in epithelial ducts during
their outgrowth.
To test whether AREG is required in the epithelium or stroma, we used recombined neonatal
mammary transplants and found that wild-type epithelium grew regardless of the stromal
genotype, whereas Areg−/− epithelium showed little or no growth in either type of stroma (Fig.
2A, B). After three weeks, non-recombined Areg−/− glands occupied ~11% of the area of paired
wild-type glands (2.0±0.8 versus 18.5±1.9 mm2; P=0.0002), and Areg−/− epithelium grown in
wild-type fat pads occupied areas that were ~22% of those occupied by wild-type epithelium
in Areg−/− fat pads (2.5±2.4 versus 11.3±5.3 mm2; P=0.004). Thus, consistent with our array
and in situ hybridization data, only epithelial AREG was required. Nevertheless, lobuloalveolar
development in response to subcutaneous slow-release estradiol pellets was qualitatively and
quantitatively normal regardless of the presence or absence of AREG in any tissue
compartment (Fig. 2E).
Stromal EGFR is required for mammary development
Our data show that during mammary development the crucial EGFR ligand AREG comes from
the epithelium. However, prior studies suggest that EGFR is enriched in the periepithelial
mammary stroma (Coleman et al., 1988; Schroeder and Lee, 1998) and that stromal rather than
epithelial EGFR is required for mammary epithelial development in vivo (Wiesen et al.,
1999). Moreover, EGFR ligands are epithelial (and stromal) mitogens, yet epithelial EGFR is
not needed for mammary epithelial development in vivo. Thus, we revisited the tissue
recombination studies that led to this somewhat paradoxical finding, this time in the presence
of estradiol pellets in order to also assess the role of EGFR in estrogen-induced alveolar
differentiation, and again found that wild-type and Egfr−/− epithelium grew in fat pads that
contained EGFR, but not in Egfr−/− fat pads (Fig. 2C, D). After 3 weeks, non-recombined
Egfr−/− glands occupied only ~4% of the area occupied by paired wild-type glands (0.5±0.2
versus 11.2±2.9 mm2; P<0.0001), and wild-type epithelium grown in Egfr−/− fat pads occupied
areas that were ~11% of those occupied by Egfr−/− epithelium in wild-type fat pads (1.3±0.7
versus 11.6±5.7 mm2; P=0.0002). Thus, in contrast to AREG, stromal EGFR indeed is required
for mammary epithelial development, whereas epithelial EGFR is dispensable. However, like
AREG, EGFR was not required for estrogen-induced lobuloalveolar development (Fig. 2E).
Epithelial ADAM17 is required for mammary development
In order for AREG on the surface of mammary epithelial cells to activate EGFR in the stroma,
it must be released by a protease, and that protease should be required in the same location as
its putative substrate. However, each of the catalytically active ADAMs on our expression
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array was highly expressed, and most, including ADAM17, had similar levels of expression
in the epithelial and stromal compartments (Fig. 1). The only notable exception was ADAM9,
which was ~50% less abundant in TEBs than distal stroma, a pattern that would not be expected
to foster the release of epithelial AREG. Interestingly, tissue inhibitor of metalloproteinases 3
(TIMP3) and TIMP1 were inversely regulated in TEBs but not ducts. Specifically, the
expression of TIMP1 was 709±213% higher in TEBs than distal stroma (P=0.0001), whereas
TIMP3 was 66±6% lower in the TEBs than in the stroma (P=0.0001) (see Table S2 in the
supplementary material). Moreover, the relative (epithelial versus stromal) and absolute (mean
overall) fluorescence intensities for TIMP1 were both significantly greater in the TEBs and
distal stroma than in the ducts and distal stroma (P<0.005), whereas the relative and absolute
values for TIMP3 were significantly lower in the TEBs and distal stroma than in the ducts and
distal stroma (P<0.005), further suggesting that TIMP1 is specifically upregulated in TEBs,
while TIMP3 is specifically downregulated (see Fig. S1 in supplementary material). Because
TIMP3 is the only known endogenous inhibitor of ADAM17 (Lee et al., 2004), this inverse
regulation of TIMP1 and TIMP3 in TEBs would tend to de-constrain ADAM17 and to increase
its net proteolytic activity in an area of active ductal invasion and branching, while limiting
the activity of other TIMP1-inhibitable ADAMs. In light of this, and in particular the
demonstrated ability of ADAM17 to process AREG in culture (Hinkle et al., 2004;Sunnarborg
et al., 2002), we evaluated ADAM17 as a possible mediator of AREG shedding during
mammary development.
Adam17−/− pups, which exhibit perinatal lethality, had 65–69% fewer mammary branches and
64–68% shorter ductal trees than their wild-type littermates at E18.5 and birth (P<0.0001; Fig.
3). Likewise, Egfr−/− neonates had 77% fewer branches (P<0.005) and 74% shorter ductal trees
(P<0.001) than their own wild-type littermates, indicating that they too had impaired fetal
mammary development (Fig. 3B, C). Two weeks after renal transplantation, Adam17−/− glands
lacked normal TEBs and had 90% less overall ductal length than contralateral wild-type glands
when exogenous estradiol was absent (P<0.0001; Fig. 4A, I). Adam17−/− transplants to cleared
mammary fat pads also underwent little or no growth in the absence of exogenous estradiol,
and even after 5 weeks, were still not significantly larger than the rudiments of newborn wild-
type mice (Fig. 4E, I). When estradiol was added, the wild-type renal transplants often filled
the fat pads by 3 weeks, whereas the Adam17−/− epithelium occupied only 20–30% of the area
of wild-type transplants at all time points up to six weeks (P<0.0001; Fig. 4B, C, J, K). Indeed,
the slope of the regression line for growth of the Adam17−/− glands in the presence of added
estradiol was not significantly different from that of a flat line (P=0.75), again indicating that
they were not catching up and that other ADAMs are unable to compensate for the absence of
ADAM17. Adam17−/− epithelium also consistently failed to grow in wild-type stroma in tissue
recombination or cleared fat pad experiments, whereas wild-type epithelium grew readily in
Adam17−/− stroma (P<0.002; Fig. 4F, J) and cleared contralateral fat pads (P=0.0002; Fig. 4D,
E, I). Thus, like AREG, ADAM17 is only required in the epithelium. Moreover, like AREG
and EGFR, its absence had no apparent effect on estrogen-induced lobuloalveolar development
(data not shown).
Local AREG administration rescues Adam17−/− mammary development in vivo
If Adam17−/− glands fail to develop due to a lack of proAREG processing, then exogenous
slow-release AREG pellets should rescue their development. Indeed, AREG pellets yielded a
2.6±0.4-fold increase in the epithelial area of paired Adam17−/− mammary glands if they were
within ~0.75 mm of the epithelium (P=0.001), whereas pellets that were ≥1.4 mm from the
epithelium had no effect on growth when compared with contralateral placebo control pellets
(Fig. 4G, H, J). The failure of distant pellets to influence growth probably reflects capture of
the AREG by intervening EGFR-expressing stromal cells or heparan sulfate proteoglycans,
which would also be abundant between the pellets and epithelium (Schuger et al., 1996).
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EGFR ligands induce branching in cultured Adam17−/− mammary organoids
If EGFR regulates mammary development downstream of ADAM17 and AREG, then its other
ligands should also foster the growth and branching of Adam17−/− and Areg−/− mammary
epithelium in culture. Indeed, when embryonic and neonatal mammary organoids were grown
in three-dimensional basement membrane gels, the wild-type, Adam17−/− and Areg−/−
organoids underwent robust growth and branching in the presence of EGF (91±8% of
organoids), TGFα (93±4%), HB-EGF (55±26%) and AREG (72±15%). By contrast, no growth
was seen when insulin was the sole growth or survival factor provided or when Egfr−/−
organoids were cultured in the presence of EGFR agonists (Fig. 5). When heparin-acrylic beads
saturated with AREG were embedded in Matrigel to mimic the AREG pellets in vivo, 67% of
organoids within 400 μm of the pellets displayed definitive growth, whereas those that were
more than 1 mm away did not grow (Fisher’s exact test P<0.001). This distinction may again
reflect sequestration of AREG.
Because ADAM17 can cleave multiple substrates, it may also influence mammary
development via other targets. TNFα, the substrate for which ADAM17 was originally named,
can stimulate growth and branching of cultured mammary epithelial cells in an EGFR-
independent, but metalloproteinase-dependent manner (Lee et al., 2000; Varela et al., 1997).
In our study, however, TNFα failed to support organoid growth in six independent experiments
(Fig. 5) and its mRNA was undetectable in developing glands (Fig. 1). Moreover, mice that
lack TNFα or either of its receptors (which are also shed by ADAM17) (Peschon et al.,
1998a) have no overt phenotype (Marino et al., 1997; Pasparakis et al., 1996; Peschon et al.,
1998b) and are lactationally competent (J. Peschon, L. Old and G. Kollias, personal
communications). Thus, TNFα is not required for mammary morphogenesis or function.
We also used genetically defined organoids to test for signaling and effector molecules that
might act up- or downstream of ADAM17 and EGFR. Thus, factors that support the growth
of Egfr−/− organoids may act downstream or independently of EGFR, whereas those that
stimulate the growth of wild-type, but not Adam17−/− organoids may act upstream. Although
Egfr−/− organoids were refractory to EGFR agonists, 53±16% did grow in response to the
ERBB3/ERBB4 ligand neuregulin-1-β1 (NRG1β1), as did wild-type, Adam17−/− and
Areg−/− organoids. Interestingly, the NRG1β1-treated organoids formed large expanding
mounds and folds rather than the florid sprouts induced by EGFR ligands (Fig. 5). Fibroblast
growth factors FGF2/bFGF and FGF7/KGF also stimulated branching in 97±2% and 85±6%
of all organoids, respectively, including Egfr−/− organoids, whereas FGF1 and FGF10 yielded
weak growth in fewer than 12% of organoids. Interestingly, the FGF2- and FGF7-treated
organoids formed hollow branches that were considerably longer than those that formed in
response to EGFR ligands and often had solid club-like ends that resembled TEBs. Thus, as
FGF2 and FGF7 support the growth of Egfr−/− organoids, they may act downstream of EGFR,
independently regulate other aspects of ductal morphogenesis or exert compensatory effects
when delivered pharmacologically.
Epithelial ADAM17, epithelial AREG and stromal EGFR are required for EGFR
phosphorylation in vivo
If ADAM17 is responsible for the release of epithelial AREG and subsequent activation of
stromal EGFR, then EGFR activation should only occur if each protein is expressed in the
appropriate compartment. Indeed, EGFR phosphorylation was only detected on immunoblots
when ADAM17 and AREG were present in the epithelium and EGFR was present in the stroma
of recombined transplants (Fig. 6). Autocrine activation was not detected in transplants
containing wild-type epithelium in an Egfr−/− stroma; however, we cannot rule out the
possibility that this reflects the limited glandular development that occurs in the absence of
stromal EGFR. These results, as well as the increased presence of the myoepithelial cell marker
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keratin 14 in transplants containing stromal EGFR and epithelial ADAM17 and AREG (Fig.
6), mirror our phenotypic observations and thus lend further credence to the conclusion that
ADAM17-mediated release of epithelial AREG is required for the activation of stromal EGFR
and ductal development.
Discussion
Branching morphogenesis is fundamental to the formation of many complex organs and
requires constant two-way communication between developing epithelia and their surrounding
stroma (Affolter et al., 2003). Indeed, bidirectional epithelial-mesenchymal crosstalk plays a
crucial role in mammary development (Veltmaat et al., 2003; Wiseman and Werb, 2002). Our
data support a model in which the EGFR axis is an essential mammary signaling system in
which ADAM17 releases epithelial AREG, which then activates stromal EGFR, thus eliciting
reciprocal responses that further orchestrate mammary epithelial development (Fig. 7). Prior
studies show that ADAM17 can process AREG in culture and suggest that it is a key regulator
of EGFR signaling, yet other ADAMs can also process EGFR ligands and genetic evidence
that ADAM17 is responsible for the release of EGFR ligands in vivo has been limited to
TGFα and HB-EGF (Blobel, 2005). Thus our study provides the first genetic evidence that
ADAM17 is an essential physiological sheddase for AREG and is the first to reveal a role for
ADAM17, the absence of which is perinatal lethal, in a postnatal developmental process. It is
also the first to show that by liberating a ligand that is available only on epithelial cells so that
it may interact with its receptor on stromal cells, ADAM17 plays an essential role in the
epithelial-stromal crosstalk that drives mammary development. Thus, although juxtacrine
activation of EGFR may occur in some situations (Borrell-Pages et al., 2003), the proteolytic
release of AREG is absolutely essential in this paracrine setting. Moreover, our results raise
new questions and possibilities concerning the cues that act upstream and downstream of this
pathway.
How is ADAM17-AREG-EGFR signaling regulated?
Mammary morphogenesis begins in late fetal development, pauses after birth and resumes in
response to ovarian hormones at the onset of puberty. Indeed, estrogens are essential and can
restore ductal development in ovariectomized mice (Daniel et al., 1987). Moreover, tissue
recombination studies show that both epithelial and stromal estrogen receptors are necessary
for mammary development (Mueller et al., 2002). Notably, EGFR ligands can rescue ductal
development in ERα-deficient mice (Kenney et al., 2003) and exogenous estradiol stimulates
EGFR and ERBB2 phosphorylation in ovariectomized mice (Sebastian et al., 1998), suggesting
that EGFR acts downstream of ERα and that it may influence mammary development in concert
with ERBB2. Thus an initial action of estrogens on stromal cells may produce stromal signals
that regulate the ADAM17-mediated release of AREG from epithelial cells, which then elicits
EGFR-mediated stromal responses that further influence the developing epithelia.
Clearly, many inputs influence the expression and activity of ADAM17, AREG and EGFR
during mammary development. For example, AREG is strongly induced by estrogens (Vendrell
et al., 2004) and is the only EGFR ligand that is adequately expressed and enriched in
developing mammary epithelium. However, several ADAMs are expressed during mammary
development, at least two of which (ADAMs 15 and 17) can process AREG (Schafer et al.,
2004). However, only ADAM17 appears to be required, as other ADAMs are unable to
compensate for its absence and triple-null mice lacking ADAM9, ADAM12 and ADAM15 are
fully able to nurse their pups (C. Blobel, personal communication). Thus, either ADAM17 is
the only physiologic AREG sheddase or it must be regulated independently of the other
available ADAMs, or both.
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Several potential avenues are available for the differential regulation of ADAM17. ADAM17
is active at the cell surface, as the removal of its propeptide domain by furin-like proprotein
convertases occurs in the trans-Golgi network (Srour et al., 2003). Notably, our results indicate
that the only known natural inhibitor of ADAM17, TIMP3 (Lee et al., 2004), is specifically
downregulated in and around invading TEBs. Thus, even though ADAM17 is ubiquitously
expressed, local downregulation of its inhibitor would tend to increase its net activity in and
around TEBs, thereby augmenting the local release of its only readily available substrate,
AREG, and enhancing EGFR activation on nearby cells. However, the upregulation of TIMP1
in TEBs may offset the absence of TIMP3 as far as other metalloproteinases are concerned,
while having no direct effect on ADAM17-mediated signaling. G-protein-coupled receptors
can induce ADAM17-mediated release of AREG and transactivation of EGFR in culture
(Gschwind et al., 2003; Lemjabbar et al., 2003); however, it remains unclear how they do so,
whether they regulate ADAM17 in mammary epithelium or which receptor agonists may be
physiologically relevant. Phosphorylation of the cytoplasmic domain of ADAM17 appears to
regulate processing of some substrates (Diaz-Rodriguez et al., 2002; Fan et al., 2003), whereas
the cytoplasmic domain is dispensable for the processing of others (Reddy et al., 2000). Integrin
α5β1 may also influence ADAM17 activity (Bax et al., 2004), and Eve-1/Sh3d19, which binds
to the cytoplasmic domain of various ADAMs, appears to promote the processing of EGFR
ligands, including AREG (Tanaka et al., 2004). Interestingly, our microarray data indicate that
Sh3d19 expression mirrors that of ADAM17 in developing mammary gland.
Does EGFR act alone or in concert with other ERBB receptors?
It is unclear whether EGFR forms homodimers or heterodimers with other ERBB receptors
during mammary development. One argument favoring the formation of homodimers is that
EGFR is enriched in the mammary stroma, whereas ERBB2 is mainly expressed in the
epithelium, ERBB3 is not detected until mammary glands mature, and ERBB4 is only
expressed during pregnancy and lactation (Schroeder and Lee, 1998). Our data indicate that
stromal EGFR regulates mammary development, yet ductal development is also impaired in
transgenic mice that express dominant-negative EGFR in the epithelium alone (Xie et al.,
1997). Although this could reflect downregulation of ERBB2 signaling, transgenic expression
of dominant-negative ERBB2 causes alveolar defects that only become apparent at parturition
(Jones and Stern, 1999). Nevertheless, Erbb2−/− mammary glands do exhibit delayed ductal
penetration and TEB defects when transplanted to cleared fat pads, but eventually catch up and
undergo lactational differentiation (Jackson-Fisher et al., 2004). In this case, only epithelial
ERBB2 is required, as the host fat pads contain ERBB2 (and EGFR). Indeed, selective ablation
of ERBB2 in mammary epithelial cells yields a similar phenotype (Andrechek et al., 2005).
Because ERBB2 has no known ligand, it requires a co-receptor; yet ERBB3 and ERBB4 are
in short supply during ductal development and our data suggest that epithelial EGFR is
expendable. Thus, epithelial EGFR-ERBB2 interactions, though not absolutely essential, may
still influence the rate of ductal development, a parameter not specifically addressed in our
study. Although our organotypic culture experiments show that the mutant epithelium is
competent to grow and branch, the ability of the organoids to respond to EGFR ligands in
culture may also reflect the possibility that epithelial EGFR signals contribute to normal ductal
development in a non-essential way. Nevertheless, prior studies (Simian et al., 2001) and our
examination of the current organoid cultures show that at least 12% of the cells in these
organotypic cultures are stromal in origin and may, therefore, also contribute to organoid
growth and branching.
EGFR may also interact with ERBB3 or ERBB4, although the latter only appears to affect
lobuloalveolar development. Genetically rescued Erbb4−/− mice develop alveolar defects
during pregnancy and lactation, yet their ductal development often surpasses that of their wild-
type siblings (Tidcombe et al., 2003). Likewise, mice that express a mammary-targeted,
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dominant-negative ERBB4 or lack the ERBB4 ligand NRG1α display impaired alveolar
differentiation but normal ductal development (Jones et al., 1999a; Li et al., 2002). Although
these alveolar effects could also involve EGFR, our data suggest that EGFR is not necessary
for alveolar development in response to estradiol or prolactin (Wiesen et al., 1999). However,
EGFR ligand-deficient dams do display more compact alveoli than wild-type mothers during
true pregnancy and lactation, when other important stimuli, such as placental lactogens, also
participate, although this could also reflect crowding as a result of impaired ductal outgrowth
(Luetteke et al., 1999). Thus, some EGFR ligands may affect lactational differentiation. Indeed,
EGF is strongly upregulated during late pregnancy and lactation (D’Cruz et al., 2002;
Schroeder and Lee, 1998), although any effects it might have could still be independent of
EGFR, as ERBB4 has high affinity for EGF in the presence of ERBB2 (Jones et al., 1999b).
Clearly, the unique growth pattern we observed in culture in response to NRG1β1 did not
require EGFR, as it occurred in Egfr−/− organoids. However, the implication that ERBB3 or
ERBB4 can affect mammary cell growth independently of EGFR does not necessarily mean
that EGFR signaling occurs independently of ERBB3 or ERBB4. Thus, it remains unclear
whether EGFR and ERBB4 interact during pregnancy and lactation, whereas it is unlikely that
they do so during ductal development, as ERBB4 is neither necessary nor expressed at that
time.
How do AREG-activated stromal cells regulate mammary epithelial development?
Because mammary epithelial development requires stromal EGFR, reciprocal stromal-to-
epithelial responses must also contribute. Other metalloproteinases undoubtedly affect
branching downstream of ADAM17, as TIMP1 inhibits branching in culture and in vivo (Fata
et al., 1999), even though it does not inhibit ADAM17. Moreover, broad-spectrum
metalloproteinase inhibitors block organoid growth in response to EGF and KGF (Simian et
al., 2001; Wiseman et al., 2003), yet the absence of ADAM17 alone does not. Notably, AREG
administration induces expression of the matrix metalloproteinase (MMP) inducer EMMPRIN,
MMP2 (gelatinase A) and MMP9 (gelatinase B) in cultured breast epithelial cells (Menashi et
al., 2003). Moreover, the activator of latent MMP2, MMP14 (MT1-MMP), is strongly induced
by EGFR activation in neonatal lung and cultured embryonic fibroblasts (Kheradmand et al.,
2002), and is present at high levels in the stromal cells adjacent to invading mammary TEBs
(Wiseman et al., 2003). Indeed, our data show that MMP2 and MMP3 (stromelysin 1) regulate
mammary ductal morphogenesis in vivo (Wiseman et al., 2003) and that MMP14 promotes
ductal development by activating MMP2 and degrading type I collagen (M. Egeblad, B. S.
Wiseman, M. D. S. and Z. W., unpublished). Nevertheless, the collagen accumulation that
characterizes Mmp14−/− mammary glands is absent in Adam17−/−, Areg−/− and Egfr−/− glands
(M. D. S. and Z. W., unpublished), either because EGFR does not regulate MMP14 during
mammary development or because collagen deposition and remodeling are not elicited in the
absence of ductal development itself. Moreover, because MMP14 is membrane bound, it can
influence epithelial behavior only indirectly, unless it is also shed.
Stromal FGF2 and FGF7/KGF may also act downstream of EGFR and may do so directly, as
they support the growth and branching of Egfr−/− mammary organoids. Indeed, their receptor,
FGFR2B, is expressed on mammary epithelial cells and is required for the initial formation of
embryonic mammary placodes, as is FGF10 (Veltmaat et al., 2003). Thus, a full understanding
of their role in subsequent processes, such as branching, will require the analysis of conditional
deletion models. However, no mammary phenotype has been described in FGF7-deficient
mice, possibly owing to compensatory mechanisms. Nevertheless, stromal FGFs and their
epithelial receptors have been shown to play critical roles in branching of the tracheal system
in Drosophila and in mammalian lung, salivary gland and kidney branching, suggesting that
similar signaling mechanisms may influence mammary branching as well (Affolter et al.,
2003).
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The pathway that we have elucidated is undoubtedly part of a larger cascade of signals that
pass back and forth between neighboring cells of the developing mammary gland. In addition,
similar pathways undoubtedly contribute to other biological processes and may be hijacked or
corrupted during the onset and evolution of disease. Indeed, ADAM17, AREG, TGFα and
EGFR are often upregulated in human breast cancer, with co-expression of the latter two
indicating a worse prognosis (Desruisseau et al., 2004; Lendeckel et al., 2005; Umekita et al.,
2000). Moreover, experimental data show that these molecules can actively contribute to the
development and progression of cancer (Borrell-Pages et al., 2003; Brandt et al., 2000;
Gschwind et al., 2003). Thus, a clearer understanding of the mechanisms that regulate
ADAM17-AREG-EGFR signaling under normal circumstances will be crucial to overcoming
them when they go awry.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Relative expression of potential interacting genes in 5-week-old mammary glands. Cy5-labeled
cDNAs from microdissected TEB- or duct-containing regions and Cy3-labeled cDNAs from
distal stroma were hybridized to long-oligonucleotide microarrays. TEB/stroma (Cy5/Cy3)
expression ratios and duct/stroma ratios are each shown for six independent experiments (lanes
1–6) and their respective means (M) using the color scale shown, with black indicating no
difference in expression, red indicating relative enrichment within the TEB or duct regions and
green representing relative enrichment in the pure distal stroma. Thus, intense red indicates a
greater than fourfold enrichment in and around TEBs or ducts. Relative expression levels for
ADAM10 are shown for two independent oligonucleotides, whereas all other genes were
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represented by a single oligonucleotide. †Genes for which the mean overall fluorescence signal
A=0.5[log2(Cy5) + log2(Cy3)] was consistently more than eight, the level below which it was
difficult distinguish true signal from noise.
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Effect of AREG and EGFR deficiency on postnatal mammary development. (A) Carmine-
stained whole mounts of paired wild-type, Areg−/− (upper left and lower right panels) and
recombined mammary transplants grown for 3 weeks in the presence of estradiol pellets. Scale
bar: 1 mm. (B) Epithelial areas of 3-week-old, estradiol-stimulated transplants with the
indicated epithelial and stromal genotypes (A−/−, Areg−/−; WT, wild type). Lines connect paired
contralateral transplants from individual host mice and single data points represent unpaired
transplants. (C) Whole mounts of wild-type, Egfr−/− and recombined 3-week-old transplants.
Scale bar: 1 mm. (D) Epithelial areas of 3-week-old transplants with the indicated epithelial
and stromal genotypes (R−/−, Egfr−/−). (E) Histological appearance of paired transplants.
Sternlicht et al. Page 18













Similar alveolar morphologies and accumulation of luminal secretory products (arrowheads)
were seen in paired transplants from individual hosts, regardless of the transplant genotype.
Scale bar: 50 μm.
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Effect of ADAM17 deficiency on prenatal mammary development. (A) Carmine-stained E18.5
mammary gland/skin whole mounts. Scale bar: 500 μm. (B) Average number of branches in
the thoracic (2 and 3) mammary glands of Adam17−/− embryos and neonates (white circles),
Egfr−/− neonates (white squares) and their respective wild-type littermates (black symbols).
(C) Overall lengths of the thoracic mammary ductal trees of Adam17−/− embryos and neonates,
Egfr−/− neonates and their wild-type littermates.
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Effect of ADAM17 deficiency on postnatal mammary development. (A–F) Whole mounts of
paired wild-type (A–E), Adam17−/− (A′–E′) and surgically recombined (F, F′) mammary glands
grown under contralateral kidney capsules (A–C, F) or in surgically cleared fat pads (D, E) for
2 (A), 3 (B, D, F) or 5 (C, E) weeks with (B, C, F) or without (A, D, E) slow-release estradiol
pellets. Adam17−/− outgrowths (arrowheads) were consistently smaller than contralateral wild-
type outgrowths, whereas the extent of estradiol-induced alveolar differentiation was similar
in each respective host (e.g. B versus B′). (G, H) Paired Adam17−/− transplants were also grown
for 3 weeks in the presence of estradiol and adjacent AREG (a) or placebo (p) pellets. The
farthest AREG pellet to yield greater-than-normal growth was ~0.75 mm from the epithelium
(double-headed arrow in G), whereas the closest pellet to have no effect on growth as compared
to its placebo control was ~1.4 mm from the epithelium (double-headed arrow in H). Scale
bar: 500 μm in A′; 2 mm in D, D′; 2.5 mm in E, E′; 1 mm in all other panels and inserts. (I)
Overall ductal lengths for newborn wild-type and Adam17−/− mammary glands, 2-week-old
renal transplants, and 3- and 5-week-old cleared fat pad grafts in the absence of added estradiol.
Error bars at birth and 2 weeks are hidden by the mean data points. (J) Epithelial areas of paired
(connected) and unpaired renal transplants with the indicated epithelial and stromal genotypes
(KO, Adam17−/−; WT, wild type). The non-recombined pairs on the left were grown for 3–6
weeks, whereas all other transplants were grown for 3 weeks in the presence of added estradiol.
Bracketed data points are those for which AREG pellets were within ~0.75 mm of the
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Adam17−/− epithelium. (K) Mean epithelial areas of non-recombined mammary glands at
various times after renal transplantation in the presence of E2.
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Effect of growth factors on genetically defined mammary organoids in Matrigel. Hoffman
modulation contrast images were taken after 7 days of growth in the presence of the indicated
supplements. Scale bar: 400 μm for KGF-treated organoids; 200 μm for all other panels.
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EGFR phosphorylation in recombined mammary glands. Tissue extracts were
immunoprecipitated (IP) with anti-EGFR antibodies, immunoblotted (IB) for phosphotyrosine
(pTyr) or phosphorylated EGFR (pEGFR; Y1068), and re-probed for EGFR. Western blots
(WB) for keratin 14 were run on the original extracts and re-probed for β-actin. Renal
transplants with the indicated epithelial and stromal genotypes (wt, wild type; 17−/−,
Adam17−/−; A−/−, Areg−/−; R−/−, Egfr−/−) were harvested 2 weeks after transplantation without
exogenous estradiol. Control tissues were harvested from 6-week-old wild-type male (M) and
female (F) mice, and Egfr−/− neonates (R−/− p0) 15 minutes after intraperitoneal injection of
EGF (2.5 mg/kg body weight) or phosphate-buffered saline (PBS).
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Model depicting epithelial-mesenchymal crosstalk and potential modifiers of ADAM17-
AREG-EGFR signaling in mammary development.
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